Review
doi: 10.1038/nrd1331.
Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes
Affiliations
- PMID: 15031735
- DOI: 10.1038/nrd1331
Item in Clipboard
Review
Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes
Nat Rev Drug Discov.
2004 Mar.
Abstract
Highly active antiretroviral therapy (HAART) based on combinations of drugs that target key enzymes in the life-cycle of human immunodeficiency virus (HIV) has considerably reduced morbidity and mortality from HIV infection since its introduction in the mid-1990s. However, the growing problem of the emergence of HIV strains that are resistant not only to individual drugs, but to whole drug classes, means that agents with new mechanisms of action are needed. Here, we describe the discovery and development of enfuvirtide (Fuzeon), the first drug to inhibit the entry of HIV-1 into host cells.
Similar articles
-
HIV entry inhibitors: a new generation of antiretroviral drugs.Acta Pharmacol Sin. 2005 Oct;26(10):1165-73. doi: 10.1111/j.1745-7254.2005.00193.x. Acta Pharmacol Sin. 2005. PMID: 16174430 Review.
-
Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations.J Med Virol. 2008 Jun;80(6):937-41. doi: 10.1002/jmv.21138. J Med Virol. 2008. PMID: 18428138
-
Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development.Lancet Infect Dis. 2004 Jul;4(7):426-36. doi: 10.1016/S1473-3099(04)01058-8. Lancet Infect Dis. 2004. PMID: 15219553 Review.
-
Resistance to enfuvirtide, the first HIV fusion inhibitor.J Antimicrob Chemother. 2004 Aug;54(2):333-40. doi: 10.1093/jac/dkh330. Epub 2004 Jul 1. J Antimicrob Chemother. 2004. PMID: 15231762 Review.
-
Entry inhibitors in the treatment of HIV-1 infection.Antiviral Res. 2010 Jan;85(1):91-100. doi: 10.1016/j.antiviral.2009.07.022. Epub 2009 Aug 14. Antiviral Res. 2010. PMID: 19683546 Review.
Cited by
-
Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain.mBio. 2020 Oct 20;11(5):e01935-20. doi: 10.1128/mBio.01935-20. mBio. 2020. PMID: 33082259 Free PMC article.
-
Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.Clin Drug Investig. 2007;27(7):469-79. doi: 10.2165/00044011-200727070-00004. Clin Drug Investig. 2007. PMID: 17563127 Clinical Trial.
-
Inhibition of murine leukemia virus envelope protein (env) processing by intracellular expression of the env N-terminal heptad repeat region.J Virol. 2005 Apr;79(8):4782-92. doi: 10.1128/JVI.79.8.4782-4792.2005. J Virol. 2005. PMID: 15795264 Free PMC article.
-
The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.J Virol. 2019 Dec 12;94(1):e01358-19. doi: 10.1128/JVI.01358-19. Print 2019 Dec 12. J Virol. 2019. PMID: 31619552 Free PMC article.
-
Peptides containing membrane-interacting motifs inhibit herpes simplex virus type 1 infectivity.Peptides. 2008 Sep;29(9):1461-71. doi: 10.1016/j.peptides.2008.04.022. Epub 2008 May 17. Peptides. 2008. PMID: 18572274 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
